Brian Baynes's Location
Boston, Massachusetts, United States, United States
Brian Baynes's Contact Details
Brian Baynes work email
- Valid
- Valid
- Valid
- Valid
Brian Baynes personal email
n/a
Brian Baynes phone numbers
About Brian Baynes
Brian Baynes is a Sustainability || Entrepreneurship at Verdox. He possess expertise in start ups, venture capital, biotechnology, entrepreneurship, life sciences and 29 more skills.
Brian Baynes Work Experience Details
-
FounderVerdox 2019 - PresentWoburn, Massachusetts, UsVerdox is developing technology for reversing climate change via electrochemical carbon capture -
Founding PillarPillar Vc 2019 - PresentBoston, Massachusetts, UsPillar VC is a Boston venture capital firm that supports founders with early-stage and seed VC funding, investing in their professional & personal growth. -
FounderPetri 2019 - PresentBoston, Ma, UsPetri develops companies attacking the world’s largest problems at the frontier of biology and engineering. -
FounderMidori Usa, Inc. 2009 - 2021Cambridge, Massachusetts, UsMidori is pioneering a novel category of products that modulate the animal microbiome to improve health and nutrition. For the production industry, our technology improves the economics, quality, and sustainability of animal protein without resorting to widespread use of antibiotics and other drugs. For companion animals, it promises better health, nutrition, and quality of life. Midori was sold to Royal DSM (AMS:DSM) in 2017. -
Member Of The Board Of Directors; Co-FounderKaleido Biosciences, Inc. 2015 - 2018Lexington, Massachusetts, UsKaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome's natural roles in promoting health. Kaleido had an IPO on the Nasdaq in early 2019. -
PartnerFlagship Pioneering 2009 - 2017Cambridge, Ma, UsFlagship Pioneering conceives, creates, resources and develops first-in-category life sciences companies. Its institutional innovation foundry, Flagship VentureLabs®, is where Flagship's team of scientific entrepreneurs systematically evolve enterprising ideas into new fields, or previously undiscovered areas of science into real-world inventions and ventures. Since its launch in 2000, the firm has applied its hypothesis-driven innovation process to originate and foster nearly 75 scientific ventures, resulting in $19 billion in aggregate value, 500+ issued patents and more than 50 clinical trials for novel therapeutic agents. Flagship's portfolio includes pioneering ventures that are transforming human health and sustainability, including: Agios Pharmaceuticals (NASDAQ: AGIO), Seres Therapeutics (NASDAQ: MCRB), Editas Medicine (NASDAQ: EDIT) and Syros Pharmaceuticals (NASDAQ: SYRS), as well as private companies including Moderna Therapeutics, Indigo Agriculture and Axcella Health. Flagship has ongoing corporate innovation alliances with several market leaders, including: AstraZeneca, Bayer Crop Science and Nestlé Health Science. -
Founder And CeoCelexion Llc 2009 - 2015UsCELEXION is a bioengineering company that develops platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. The company’s technologies include the SECANT platform for engineering high performance protein products, a library of human antibodies for therapeutic lead generation, enzymatic pathways for synthesis of a variety of high-value renewable chemicals and materials from wastes and other inexpensive precursors, and a novel family of enzymes for manipulation of chromosome-sized DNA. Celexion was sold to Agenus (NASDAQ:AGEN) in 2015. -
Chief Scientific Officer And FounderCodon Devices 2004 - 2009Codon Devices focused on enabling commercial applications of synthetic biology. Codon Devices' proprietary synthesis and design technologies improve the productivity, throughput and flexibility of its industrial, pharmaceutical and academic customers in a paradigm shift to what the company calls Constructive Biology(TM). The company's focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and energy. Codon Devices' BioFAB(TM) platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology. Codon Devices is currently scaling the platform to design and construct engineered genetic devices hundreds of kilobases to megabases in length. Codon Devices was sold to Gen9 (now Ginkgo Bioworks, NYSE:DNA) in 2009.
-
Research EngineerExxonmobil 1996 - 2001Us
Brian Baynes Skills
Start Ups
Venture Capital
Biotechnology
Entrepreneurship
Life Sciences
Technology Transfer
Cleantech
Commercialization
Biofuels
R&d
Molecular Biology
Lifesciences
Protein Chemistry
Renewable Energy
Biochemistry
Corporate Development
Genomics
Biopharmaceuticals
Drug Discovery
Angel Investing
Nanotechnology
Clean Technology
Patents
Deal Sourcing
Alternative Energy
Process Simulation
Start Up Ventures
Biomass
Technology Evaluation
Venture Financing
New Venture Development
Green Technology
Bioinformatics
Open Innovation
Brian Baynes Education Details
-
Massachusetts Institute Of TechnologyChemical Engineering -
University Of DelawareChemical Engineering
Frequently Asked Questions about Brian Baynes
What company does Brian Baynes work for?
Brian Baynes works for Verdox
What is Brian Baynes's role at the current company?
Brian Baynes's current role is Sustainability || Entrepreneurship.
What is Brian Baynes's email address?
Brian Baynes's email address is ba****@****mit.edu
What is Brian Baynes's direct phone number?
Brian Baynes's direct phone number is +161786*****
What schools did Brian Baynes attend?
Brian Baynes attended Massachusetts Institute Of Technology, University Of Delaware.
What skills is Brian Baynes known for?
Brian Baynes has skills like Start Ups, Venture Capital, Biotechnology, Entrepreneurship, Life Sciences, Technology Transfer, Cleantech, Commercialization, Biofuels, R&d, Molecular Biology, Lifesciences.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial